In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease

Eur J Med Chem. 2008 Oct;43(10):2229-37. doi: 10.1016/j.ejmech.2007.12.016. Epub 2007 Dec 28.

Abstract

5-arylethenylbenzofuroxan derivatives with high in vitro anti-Trypanosoma cruzi activity were studied in vivo using acute murine models of Chagas' disease. The selected compounds, as pure isomeric forms, 1, 2, 3 and 4, or as equimolecular mixture of geometric isomers, 1:2, 3:4, 5:6 were studied against different T. cruzi strains. Consequently, Tulahuen 2 strain, Colombiana strain (resistant to Nifurtimox and Benznidazole), and two different wild strains, one isolated from the wild reservoir Didelphis marsupialis and another one from Uruguayan patients, were selected. No relevant signs of in vivo toxicity were observed with the benzofuroxans orally administered. Compound 1 and the mixture of isomers 1:2 were the best for treating infection against the four studied strains.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease / therapy
  • Animals
  • Antibodies, Protozoan / metabolism
  • Benzoxazoles / administration & dosage
  • Benzoxazoles / chemistry
  • Benzoxazoles / pharmacology
  • Benzoxazoles / therapeutic use*
  • Chagas Disease / drug therapy*
  • Chagas Disease / immunology
  • Chagas Disease / pathology
  • Chagas Disease / therapy
  • Disease Models, Animal
  • Female
  • Mice
  • Parasitemia / drug therapy
  • Treatment Outcome
  • Trypanosoma cruzi / drug effects

Substances

  • Antibodies, Protozoan
  • Benzoxazoles
  • benzofuroxan